对于在地平线上的滤泡性淋巴瘤新疗法

最近批准的针对性和免疫治疗药物帮助诊断为滤泡性淋巴瘤寿命更长的患者。了解可用的治疗方案可以帮助医生建议他们的病人初诊或复发性或难治性滤泡性淋巴瘤最适当的治疗。

近40年来，化疗是照顾的滤泡性淋巴瘤，这是第二个最常见的非霍奇金淋巴瘤最常见的生长缓慢的淋巴瘤的标准。护理的标准已与中，通过与肿瘤细胞表面分子干扰阻断病情的发展靶向药物的问世改变，并与免疫治疗药物，争取人体自身的免疫系统来对抗疾病。

“We’ve seen a paradigm shift in the past five years, with most new treatment regimens incorporating novel targeted or immunotherapeutic agents,” saidNathan Fowler, M.D.，副教授淋巴瘤and Myeloma。

As a result of the shifting standard of care, outcomes have improved for patients with follicular lymphoma, Fowler said.

“谁的病人已收到现行标准疗法几个长期随访研究表明，不同患者的10到15年前，”他说，“大部分患者将在今天不是他们的疾病死亡。”

The standard of care for follicular lymphoma continues to evolve. Several multicenter phase III randomized controlled trials comparing new treatment regimens with standard therapies are ongoing or recently completed, and Fowler expects some of these new regimens to be approved by the Food and Drug Administration within the next few years.

The combination of rituximab and the immune modulator lenalidomide, a regimen commonly known as R2, is in phase III trials for patients with previously untreated or relapsed/refractory follicular lymphoma. Fowler expects to see preliminary results in the coming months.

A phase III trial of obinutuzumab and chemotherapy in patients with previously untreated follicular lymphoma also recently completed enrollment. Fowler anticipates the combination’s approval as a first-line therapy.

Two ongoing phase III trials are evaluating the Bruton tyrosine kinase inhibitor ibrutinib, which is approved for the treatment of other slow-growing lymphomas, for patients with follicular lymphoma. Fowler is the national principal investigator for one of the trials, which will soon begin enrolling patients at MD Anderson.

Chemotherapy can create long-term toxic side effects, Fowler said.

“Patients with follicular lymphoma are surviving longer today, so we’re looking to targeted and immunotherapy drugs because patients are going to have to live with this disease along with any side effects of the treatment.”

Read more about advances in follicular lymphoma treatment inOncolog。